Do statins improve heart failure outcome in post-myocardial infarction patients with moderate to severe left ventricular dysfunction?

Congestive Heart Failure

Volumn 16, Issue 4, 2010, Pages 181-186

  Sankaranarayanan, Rajiv ^a   Maini, Sameer ^b   James, Michael Anthony ^b   Burtchaell, Stephanie ^b   Chatterjee, Amit K ^c  

^a Manchester Heart Centre   (United Kingdom)

^b Taunton Hospital   (United Kingdom)

^c ROYAL BLACKBURN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN; SPIRONOLACTONE;

AGED; ARTICLE; BLOOD CLOT LYSIS; CARDIAC RESYNCHRONIZATION THERAPY; CHOLESTEROL BLOOD LEVEL; DEFIBRILLATOR; DISEASE SEVERITY; DRESSLER SYNDROME; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; FEMALE; GREAT BRITAIN; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77955137563     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2010.00165.x     Document Type: Article

References (37)

1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007, 93(9):1137-1146.
2. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998, 97:282-289.
3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
4. Pedersen TR, Kjekshus J, Berg K. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease-the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
5. Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357.
7. Shepherd J, Blauw GJ, Murphy MB. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
8. Sever PS, Dahlöf B, Poulter NR. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
9. Ray J, Gong Y, Sykora K, Tu J. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005, 165(1):62-67.
10. Segal R, Pitt B, Poole Wilson PP. Effects of HMG-CoA reductase inhibitors (statins) in patients with heart failure. Eur J Heart Fail 2000, 2(suppl):96.
11. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004, 93:1124-1129.
12. Horwich TB, Hamilton MA, Maclellan WR. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002, 8:216-224.
13. Kloner RA, Jennings RB. Consequence of brief ischaemia, stunning, preconditioning and their clinical implications. Circulation 2001, 104(25):3158-3167.
14. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004, 43:642-648.
15. Schwartz GG, Olsson AG, Ezekowitz MD. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomised controlled trial. JAMA 2001, 285:1711-1718.
16. Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000, 35:1-10.
17. Scirica BM, Morrow DA, Cannon CP. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006, 47(11):2326-2331.
18. Kjekshus J, Apetrei E, Barrios V. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357(22):2248-2261.
19. Gissi-HF Investigators, Tavazzi L, Maggioni AP. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9645):1231-1239.
20. Fonarow GC. Statins and n-3 fatty acid supplementation in heart failure. Lancet 2008, 372(9645):1195-1196.
21. Young-Xu Y, Jabbour S, Goldberg R. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003, 92:1379-1383.
22. Sola S, Mir MQ, Lerakis S. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006, 47(2):332-337.
23. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126-1131.
24. Wang TD, Wu CC, Chen WJ. Dyslipidemias have a detrimental effect on left ventricular systolic function in patients with a first acute myocardial infarction. Am J Cardiol 1998, 81:531-537.
25. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996, 348:1079-1082.
26. Bauersachs J, Galuppo P, Fraccarollo D. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001, 104:982-985.
27. Hayashidani S, Tsutsui H, Shiomi T. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002, 105:868-873.
28. Maack C, Kartes T, Kilter H. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003, 108:1567-1574.
29. Torre-Amione G, Bozkurt B, Deswal A, Mann DL. An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol 1999, 14:206-210.
30. Rauchhaus M, Doehner W, Francis DP. Plasma cytokine parameters and mortality in patients with heart failure. Circulation 2000, 102:3060-3067.
31. Kaneko K, Kanda T, Yamauchi Y. C-reactive protein in dilated cardiomyopathy. Cardiology 1999, 91:215-219.
32. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003, 107:2493-2498.
33. Strehlow K, Wassmann S, Bohm M, Nickenig G. Angiotensin AT1 receptor over-expression in hypercholesterolaemia. Ann Med 2000, 32:386-389.
34. Indolfi C, Di LE, Perrino C. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 2002, 106:2118-2124.
35. Ferrier KE, Muhlmann MH, Baguet JP. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002, 39:1020-1025.
36. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000, 356:930-933.
37. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997, 18(suppl):S137-S144.